Gilead Sciences, Inc. (GILD) Shares Sold by NorthCoast Asset Management LLC

Marco Green
January 21, 2018

Healthcare Value Capital Llc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $106.03B market cap company.

Gilead Sciences (GILD) traded down $0.19 during mid-day trading on Tuesday, reaching $80.98. About 33,499 shares traded or Infinity% up from the average. It has underperformed by 38.50% the S&P500.

Addenda Capital Inc increased its stake in Manulife Finl Corp (MFC) by 7.26% based on its latest 2017Q3 regulatory filing with the SEC. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $2.87 by $0.12. The institutional investor held 1,520 shares of the military and government and technical company at the end of 2017Q3, valued at $472,000, up from 200 at the end of the previous reported quarter. Highvista Strategies Llc who had been investing in Aercap Holdings Nv for a number of months, seems to be less bullish one the $8.55B market cap company. The stock decreased 0.25% or $0.63 during the last trading session, reaching $253.99. About 4.30M shares traded. Manulife Financial Corporation (NYSE:MFC) has risen 24.00% since January 19, 2017 and is uptrending. It has underperformed by 16.70% the S&P500. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eighteen have given a buy rating to the company's stock. According to the most recent data, Gilead Sciences, Inc. has a 52-week high of $86.27 and a 52-week low of $63.76.

Empirical Finance LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) earned "Buy" rating by Jefferies on Wednesday, October 5. (NASDAQ:GILD) has "Hold" rating given on Tuesday, October 3 by Needham. As per Tuesday, August 1, the company rating was maintained by BTIG Research. Also, the current price highlights a discount of 70.72% to analysts' high consensus price target. H.C. Wainwright maintained it with "Buy" rating and $1500 target in Thursday, August 10 report. Credit Suisse Group reissued a buy rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. (NASDAQ:GILD) opened at $81.17 on Friday. The rating was maintained by Maxim Group with "Buy" on Wednesday, October 28.

Since August 1, 2017, it had 0 insider purchases, and 12 insider sales for $43.50 million activity. Lockheed Martin Investment Management Co. now owns 5,000 shares of the biopharmaceutical company's stock valued at $358,000 after purchasing an additional 1,000 shares during the last quarter. It also increased its holding in Portland General Electric Co. (NYSE:SAVE) for 349,801 shares.

VANGUARD GROUP INC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD). Mawer Management Limited reported 578,170 shares or 0.4% of all its holdings. During the same period in the prior year, the business posted $2.75 earnings per share.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Ifc Inc Fl invested in 0.07% or 12,758 shares. Ingalls And Snyder Ltd Liability Corporation holds 0% in Synergy Pharmaceuticals Inc. The count of Hold ratings in that period was 0. Augustine Asset Management invested in 2.65% or 51,158 shares. Of all equities tracked, Gilead Sciences had the 8th highest net in-flow for the day. Prelude Capital Mgmt Limited Liability Com holds 0.07% in Gilead Sciences, Inc.

COPYRIGHT VIOLATION WARNING: "Investors Buy Gilead Sciences (GILD) on Weakness on Insider Selling" was reported by BBNS and is the property of of BBNS.

Cognios Capital Llc, which manages about $312.20M and $247.23M US Long portfolio, upped its stake in Foot Locker Inc (NYSE:FL) by 9,887 shares to 49,473 shares, valued at $1.74 million in 2017Q3, according to the filing. Amer Mngmt accumulated 39,546 shares. Rand Wealth Lc has invested 0.16% in Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, September 7. (NASDAQ:GILD). Rhenman Partners Asset Mngmt holds 155,551 shares or 1.61% of its portfolio. M stated it has 6,091 shares. Whittier Tru reported 169,995 shares. 6,092 were accumulated by Next Fin Grp. The company stock experienced a -0.7% move to arrive at $81.17. 10,932 were accumulated by Dreman Value Mgmt L L C. Nomura Asset Mgmt Limited owns 821,060 shares or 0.86% of their United States portfolio. It also reduced its holding in Ishares Tr (IJR) by 6,122 shares in the quarter, leaving it with 48,221 shares, and cut its stake in Schwab Strategic Tr (SCHX).

Since July 31, 2017, it had 0 insider buys, and 6 insider sales for $34.06 million activity. 350 shares were sold by Colan Brian P, worth $107,167 on Tuesday, August 15. Cheyne Capital Management Uk Llp bought 1.49 million shares as the company's stock declined 35.42% while stock markets rallied.

Investors sentiment decreased to 1.27 in 2017 Q3. It increased, as 59 investors sold SAVE shares while 48 reduced holdings. 47 funds opened positions while 119 raised stakes. 221.38 million shares or 1.04% less from 223.70 million shares in 2017Q2 were reported. Morgan Stanley maintained Gilead Sciences, Inc. Provident holds 5.23% or 381,058 shares in its portfolio. Ubs Asset Management Americas reported 13,076 shares stake. Centurylink, a Colorado-based fund reported 21,013 shares. Edgar Lomax Communication Va has 50,775 shares for 1.11% of their portfolio. (NYSE:PRLB). Manufacturers Life Insurance The has invested 0% in Proto Labs, Inc. Boston Ptnrs reported 90,726 shares. (NYSE:SAVE) for 559,481 shares. Cetera Advisor Ltd Limited Liability Company stated it has 14,024 shares. Healthcare Value Cap Ltd Co accumulated 75,000 shares. Point72 Asia (Hong Kong) Limited reported 2,981 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article